Taten Trial (Solti-1716) Targeting Non-Luminal Disease By Pam50 With Pembrolizumab + Paclitaxel In Hormone Receptor-Positive/Her2-Negative (Hr+/Her2-) Metastatic Breast Cancer (Mbc): Interim Analysis
Paclitaxel;Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Taten Trial (Solti-1716) Targeting Non-Luminal Disease By Pam50 With Pembrolizumab + Paclitaxel In Hormone Receptor-Positive/Her2-Negative (Hr+/Her2-) Metastatic Breast Cancer (Mbc): Interim Analysis ### Output: Paclitaxel;Pembrolizumab